Neoadjuvant Chemotherapy Alone or Combined with EGFR-Directed Targeted Therapy or Anti-PD-1 Immunotherapy for Locally Advanced Lacrimal Sac and Nasolacrimal Duct Carcinomas

REFERENCES

• Parmar DN, Rose GE. Management of lacrimal sac tumours. Eye (Lond). 2003;17(5):599–606. doi:10.1038/sj.eye.6700516.
   PubMed Web of Science ®Google Scholar
• Stefanyszyn MA, Hidayat AA, Pe’er JJ, et al. Lacrimal sac tumors. Ophthalmic Plast Reconstr Surg. 1994;10(3):169–184. doi:10.1097/00002341-199409000-00005.
   PubMed Web of Science ®Google Scholar
• Hornblass A, Jakobiec FA, Bosniak S, et al. The diagnosis and management of epithelial tumors of the lacrimal sac. Ophthalmology. 1980;87(6):476–490. doi:10.1016/S0161-6420(80)35205-6.
   PubMed Web of Science ®Google Scholar
• Valenzuela AA, Selva D, McNab AA, et al. En bloc excision in malignant tumors of the lacrimal drainage apparatus. Ophthalmic Plast Reconstr Surg. 2006;22(5):356–360. doi:10.1097/01.iop.0000235819.06507.b1.
   PubMed Web of Science ®Google Scholar
• El-Sawy T, Frank SJ, Hanna E, et al. Multidisciplinary management of lacrimal sac/nasolacrimal duct carcinomas. Ophthalmic Plast Reconstr Surg. 2013;29(6):454–457. doi:10.1097/IOP.0b013e31829f3a73.
   PubMed Web of Science ®Google Scholar
• Zhang R, Qian J, Meng F, et al. A staged procedure in the treatment of primary lacrimal sac epithelial malignancy: a retrospective cases analysis. Ophthalmic Plast Reconstr Surg. 2019;35(2):187–192. doi:10.1097/IOP.0000000000001206.
   PubMed Web of Science ®Google Scholar
• Trodello C, Pepper JP, Wong M, et al. Cisplatin and cetuximab treatment for metastatic cutaneous squamous cell carcinoma: a systematic review. Dermatol Surg. 2017;43(1):40–49. doi:10.1097/DSS.0000000000000799.
   PubMed Web of Science ®Google Scholar
• Mendelsohn J, Baselga J. Status of epidermal growth factor receptor antagonists in the biology and treatment of cancer. J Clin Oncol. 2003;21(14):2787–2799. doi:10.1200/JCO.2003.01.504.
   PubMed Web of Science ®Google Scholar
• Sigismund S, Avanzato D, Lanzetti L. Emerging functions of the EGFR in cancer. Mol Oncol. 2018;12(1):3–20. doi:10.1002/1878-0261.12155.
   PubMed Web of Science ®Google Scholar
• El-Sawy T, Sabichi AL, Myers JN, et al. Epidermal growth factor receptor inhibitors for treatment of orbital squamous cell carcinoma. Arch Ophthalmol. 2012;130(12):1608–1611. doi:10.1001/archophthalmol.2012.2515.
   PubMedGoogle Scholar
• Gross ND, Miller DM, Khushalani NI, et al. Neoadjuvant cemiplimab for stage II to IV cutaneous squamous-cell carcinoma. N Engl J Med. 2022;387(17):1557–1568. doi:10.1056/NEJMoa2209813.
   PubMed Web of Science ®Google Scholar
• Ferrarotto R, Amit M, Nagarajan P, et al. Pilot phase II trial of neoadjuvant immunotherapy in locoregionally advanced, resectable cutaneous squamous cell carcinoma of the head and neck. Clin Cancer Res. 2021;27(16):4557–4565. doi:10.1158/1078-0432.CCR-21-0585.
   PubMed Web of Science ®Google Scholar
• Migden MR, Rischin D, Schmults CD, et al. PD-1 blockade with cemiplimab in advanced cutaneous squamous-cell carcinoma. N Engl J Med. 2018;379(4):341–351. doi:10.1056/NEJMoa1805131.
   PubMed Web of Science ®Google Scholar
• Shalhout SZ, Emerick KS, Kaufman HL, et al. Immunotherapy for nonmelanoma skin cancer. Curr Oncol Rep. 2021;23:125. doi:10.1007/s11912-021-01120-z.
   PubMed Web of Science ®Google Scholar
• Grob J-J, Gonzalez R, Basset-Seguin N, et al. Pembrolizumab monotherapy for recurrent or metastatic cutaneous squamous cell carcinoma: a single-arm phase II trial (KEYNOTE-629). J Clin Oncol. 2020;38(25):2916–2925. doi:10.1200/JCO.19.03054.
   PubMed Web of Science ®Google Scholar
• Stevenson ML, Wang CQ, Abikhair M, et al. Expression of programmed cell death ligand in cutaneous squamous cell carcinoma and treatment of locally advanced disease with pembrolizumab. JAMA Dermatol. 2017;153(4):299–303. doi:10.1001/jamadermatol.2016.5118.
   PubMed Web of Science ®Google Scholar
• Rischin D, Khushalani NI, Schmults CD, et al. Integrated analysis of a phase 2 study of cemiplimab in advanced cutaneous squamous cell carcinoma: extended follow-up of outcomes and quality of life analysis. J Immunother Cancer. 2021;9(8):e002757. doi:10.1136/jitc-2021-002757.
   PubMed Web of Science ®Google Scholar
• Migden MR, Khushalani NI, Chang ALS, et al. Cemiplimab in locally advanced cutaneous squamous cell carcinoma: results from an open-label, phase 2, single-arm trial. Lancet Oncol. 2020;21(2):294–305. doi:10.1016/S1470-2045(19)30728-4.
   PubMed Web of Science ®Google Scholar
• Gross N, Ferrarotto R, Nagarajan P, et al. Phase II study of neoadjuvant cemiplimab prior to surgery in patients with stage III/IV (M0) cutaneous squamous cell carcinoma of the head and neck (CSCC-HN). Ann Oncol. 2019;30(910):v910. doi:10.1093/annonc/mdz394.071.
   Google Scholar
• Goldfarb JA, Ferrarotto R, Gross N, et al. Immune checkpoint inhibitors for treatment of periorbital squamous cell carcinoma. Br J Ophthalmol. 2023;107(3):320–323. doi:10.1136/bjophthalmol-2021-319417.
   PubMed Web of Science ®Google Scholar
• Guthrie TH, Porubsky ES, Luxenberg MN, et al. Cisplatin-based chemotherapy in advanced basal and squamous cell carcinomas of the skin: results in 28 patients including 13 patients receiving multimodality therapy. J Clin Oncol. 1990;8(2):342–346. doi:10.1200/JCO.1990.8.2.342.
   PubMed Web of Science ®Google Scholar
• Denic S. Preoperative treatment of advanced skin carcinoma with cisplatin and bleomycin. Am J Clin Oncol. 1999;22(1):32–34. doi:10.1097/00000421-199902000-00008.
   PubMed Web of Science ®Google Scholar
• Sadek H, Azli N, Wendling JL, et al. Treatment of advanced squamous cell carcinoma of the skin with cisplatin, 5-fluorouracil, and bleomycin. Cancer. 10.1002/1097-0142(19901015)66:8<1692:aid-cncr2820660807>3.0.co;2-y. 1990;66(8):1692–1696. doi:10.1002/1097-0142(19901015)66:8<1692:AID-CNCR2820660807>3.0.CO;2-Y.
   PubMed Web of Science ®Google Scholar
• Shepler TR, Prieto VG, Diba R, et al. Expression of the epidermal growth factor receptor in conjunctival squamous cell carcinoma. Ophthalmic Plast Reconstr Surg. 2006;22(2):113–115. doi:10.1097/01.iop.0000202609.92772.c3.
   PubMed Web of Science ®Google Scholar
• Maubec E, Petrow P, Scheer-Senyarich I, et al. Phase II study of cetuximab as first-line single-drug therapy in patients with unresectable squamous cell carcinoma of the skin. J Clin Oncol. 2011;29(25):3419–3426. doi:10.1200/JCO.2010.34.1735.
   PubMed Web of Science ®Google Scholar
• Lewis CM, Glisson BS, Feng L, et al. A phase II study of gefitinib for aggressive cutaneous squamous cell carcinoma of the head and neck. Clin Cancer Res. 2012;18(5):1435–1446. doi:10.1158/1078-0432.CCR-11-1951.
   PubMed Web of Science ®Google Scholar